22 May 2007, London, UK: Ark Therapeutics Group plc announces today that it has
been given clearance by the US Recombinant DNA Advisory Committee (RAC) for its
planned Phase III US clinical study of Trinam(R), Ark's novel gene-based therapy
to prevent haemodialysis access graft blockage.
